Aurinia Pharmaceuticals Aktie [WKN DE: A1W7D4 / ISIN: CA05156V1022]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Aurinia Pharmaceuticals Inc

18.11.24		Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis (Businesswire)
14.11.24		Aurinia to Participate in Jefferies London Healthcare Conference (Businesswire)
07.11.24		Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth (Businesswire)
30.10.24		Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 (Businesswire)
24.09.24		Aurinia Announces Approval Of LUPKYNIS In Japan - Quick Facts (RTTNews)
24.09.24		Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis (Businesswire)
13.09.24		Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference (Businesswire)
12.09.24		Aurinia Announces Board Restructuring (Businesswire)
05.09.24		Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial (Businesswire)
28.08.24		Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference (Businesswire)
01.08.24		Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results (Businesswire)
19.07.24		Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024 (Businesswire)
02.07.24		Aurinia to Participate in Upcoming Investor Healthcare Conferences (Businesswire)
14.06.24		Aurinia Announces 2024 Annual General Meeting Results (Businesswire)
05.06.24		Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 (Businesswire)
04.06.24		Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce (Businesswire)
04.06.24		Aurinia Provides Update on Proxy Statement (Businesswire)
30.05.24		Aurinia Will Attend 2024 Jefferies Global Healthcare Conference (Businesswire)
14.05.24		Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024 (Businesswire)
09.05.24		Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024 (Businesswire)
07.05.24		Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference (Businesswire)
02.05.24		Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results (Businesswire)
01.05.24		Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month (Businesswire)
30.04.24		The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program (Businesswire)
15.04.24		Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024 (Businesswire)
09.04.24		Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference (Businesswire)
29.02.24		Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program (Businesswire)
27.02.24		Aurinia to Participate in Upcoming Investor Healthcare Conferences (Businesswire)
15.02.24		Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value (Businesswire)
05.02.24		Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024 (Businesswire)
05.01.24		Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results (Businesswire)
20.12.23		Aurinia Submits IND Application to US Food & Drug Administration for AUR 200 (Businesswire)
13.11.23		Aurinia Says Its Partner Otsuka Filed NDA For Voclosporin In Japan (RTTNews)
13.11.23		Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan (Businesswire)
07.11.23		Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNIS? (voclosporin) for Patients with Lupus Nephritis at ACR 2023 (Businesswire)
02.11.23		Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNIS? for Managing Lupus Nephritis (Businesswire)
02.11.23		Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results (Businesswire)
26.10.23		Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis (Businesswire)
19.10.23		Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023 (Businesswire)
21.09.23		Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital (Businesswire)
21.08.23		Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines (Businesswire)
03.08.23		Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results (Businesswire)
20.07.23		Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023 (Businesswire)
30.06.23		Pre-market Movers: RNLX, BHG, PALT, ROOT, GHSI… (RTTNews)
30.06.23		Aurinia Pharma Gains 15% In Premarket As It Explores Strategic Options Including Sale (RTTNews)
29.06.23		Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value (Businesswire)
20.06.23		Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy (Businesswire)
01.06.23		LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone (Businesswire)
26.05.23		Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees (Businesswire)
17.05.23		Aurinia Announces 2023 Annual General Meeting Results (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

NVIDIA vor Q3-Ergebnissen: Hohe Erwartungen und höhere Kursziele für den KI-Giganten

Solana noch in diesem Jahr bei 300 US-Dollar?

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

BlackRocks Bitcoin-ETF überholt Gold-ETF

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	22.11.2024 17:23
Kaufwert:	EUR
	Hinzufügen Speichern